Non-small cell lung cancer
Not recruitingStudy on the Safety and Effectiveness of Telisotuzumab Vedotin for Patients with Previously Treated c-Met Positive Non-Small Cell Lung Cancer
Study on the Safety and Effectiveness of Telisotuzumab Vedotin for Patients with Previously Treated c-Met Positive Non-Small Cell Lung Cancer
- Disease:Non-small cell lung cancer
- Substances:Telisotuzumab Vedotin
Spain- Participants:18–64 years · 65+ years
- Substances:Telisotuzumab Vedotin
- Sponsor:AbbVie Deutschland GmbH & Co. KG









